Exceling at Accelerating in Rare Disease Drug Development Blog Post
By: Rajesh Krishna, PhD, FAAPS and Steve Sibley According to the National Institutes of Health, more than 30 million people in the United States are affected by a rare disease….
Using Modeling & Simulation to Develop a Dosing Regimen for a Bispecific Antibody for Pediatric Cancer Blog Post
Bispecific antibodies are an emerging class of antibodies developed in recent years that provide new possibilities for cancer therapy. They can target two ligands simultaneously making them more versatile than...
Tips & Tricks for Streamlining Non-compartmental Pharmacokinetic Analysis Blog Post
These Phoenix tips and tricks will help you exclude Lambda Z, name partial areas, and run a steady-state NCA.
D360 as your organization’s extendable and central data engine Blog Post
D360 is an industry-leading scientific data informatics platform providing a flexible, scalable, and customizable enterprise data integration solution. In addition to its versatile desktop-application used by thousands of medicinal chemists,…
Physiologically-Based Pharmacokinetic Modeling & Simulation to Support Asciminib NDA Submission & Inform Drug Product Label Blog Post
Physiologically based pharmacokinetic (PBPK) modeling and simulation has become an established approach to assess drug-drug interaction (DDI) liabilities involving CYP enzymes, with transporters and/or absorption-related mechanisms evolving in its acceptance…
New FDA Validator Rules V1.6 Explained Blog Post
In this blog, we explore what you need to know about the update to the new FDA Validator Rules V1.6 & answer key questions about the changes.
Simcyp Secondary Intelligence Software Blog Post
Transcript Introducing Secondary Intelligence. The first and only evidence based quantitative technology for managing off target safety issues in pharmaceutical r and d. Safety issues contribute to around twenty five...
Certara Awarded NIH Contract for Toxicology Consulting Support Blog Post
Certara toxicology experts to support NIH’s BPN and HEAL drug development programs for nervous system disorders including addiction and chronic pain Princeton, N.J., January 10, 2023 – Certara, Inc. (Nasdaq:…
Ghent University wins the 2021/22 Certara-Simcyp Grant and Partnership Scheme Blog Post
PRINCETON, N.J., January 9, 2023 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Ghent University (Belgium) submitted the successful bid for the 2021/22 Grant and…
